Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein ReceptorDouglas G. Johns, Harold B. Wood, Fa‐Xiang Ding et al.|Circulation|2023Cited by 141
The effect of histone deacetylase inhibitors on the efficiency of the CRISPR/Cas9 systemYmer M. Bjornson, Jennifer M. Johnston|Biochemistry and Biophysics Reports|2023Cited by 4
The enhancement of CRISPR/Cas9 gene editing using metforminJaedyn L. Rollins, Jennifer M. Johnston|Biochemistry and Biophysics Reports|2023Cited by 0